April 2026 STAAR Surgical Company received U.S. FDA approval for its next-generation EVO/EVO+ Visian Implantable Collamer Lens (ICL) with expanded indications for the correction of myopia and astigmatism. The approval broadens the company's implant portfolio and expands access to refractive vision correction procedures.
February 2026 Alcon launched the Clareon PanOptix Pro intraocular lens (IOL) in select international markets, expanding its premium cataract surgery portfolio. The new ocular implant incorporates advanced optical technology designed to improve near, intermediate, and distance vision after cataract surgery.
October 2025 Johnson & Johnson MedTech (Johnson & Johnson Vision) received CE Mark approval for an expanded portfolio of TECNIS Odyssey intraocular lenses, strengthening its premium IOL offerings for cataract and refractive surgery across Europe.
June 2025 Bausch + Lomb commercially launched the enVista Aspire™ Intermediate Optimized IOL in the United States following FDA approval. The launch expands the company's cataract surgery portfolio by providing surgeons with an additional premium monofocal intraocular lens option designed to improve intermediate vision.